Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HRS 2018 Wrap-Up: Tendril Lead Failures; Metaanalysis Of Contact-Force Catheter; LuxCath's OmniView; More Micra Results

Executive Summary

The 2018 Heart Rhythm Society scientific sessions in Boston covered a variety of presentations of new electrophysiology clinical data, including a report on the failure of St. Jude's Tendril leads, a meta-analysis of contact-force catheters for atrial-fibrillation ablation, and new data on Medtronic's Micra leadless pacemaker.

You may also be interested in...



Medtronic’s Micra Transcatheter Pacemaker Improves Cardiac Function In MARVEL 2

New clinical trial results show accelerometer-based atrial sensing with an automated, enhanced algorithm delivered by Medtronic’s leadless ventricular pacemaker can significantly improve atrioventricular synchrony in patients with sinus rhythm and atrioventricular block.

Medtronic Expects EV ICD To Reduce ICD Complications, Costs

The pivotal trial of Medtronic’s EV ICD, an implantable cardioverter defibrillator without a transvenous lead, has begun with implants in Illinois and New Zealand. The study will measure device-related complications with the device over six months and test EV ICD's ability to stop ventricular fibrillation.

HRS 2017: Medtronic And Boston Scientific's Less-Invasive CRM Devices Perform As Hoped In Real-World Registries

Results from the post-approval trials of Medtronic's Micra Transcatheter Pacing System and Boston Scientific's S-ICD presented at the Heart Rhythm Society Scientific Sessions in Chicago show these "leadless" devices can be implanted in "real world" patients with acute outcomes similar to those of the pre-market trials that had more restrictive inclusion criteria.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT122702

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel